Medically reviewed by Lindsay Cook, PharmD Key Takeaways Concerta and Vyvanse are both long-acting stimulant medications taken to treat ADHD, but they differ in their formulations and additional uses.

Shire announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse (lisdexamfetamine dimesylate) compared to Concerta (methylphenidate HCl) in patients with Attention Deficit ...

Shire has unveiled plans for two head-to-head studies comparing its attention-deficit hyperactivity disorder drug Vyvanse with Johnson & Johnson's rival product Concerta. Shire has unveiled plans for ...

For 2011, Vyvanse turned in $805 million in sales. Concerta brought in $1.4 billion in 2010, its last full year without generic competiton. Besides looking for an edge in ADHD, Shire is studying ...

Prospectively designed head-to-head clinical trials provide important information to physicians, patients, caregivers and payers to make informed choices. The two Phase 4 clinical trials are designed ...

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse ® (lisdexamfetamine dimesylate) compared with Concerta (methylphenidate HCl) ...

As kids start heading back to school--and getting back on their ADHD meds--one analyst expected Shire's ($SHPG) Vyvanse to steal market share from Johnson & Johnson's ...

Shire has amassed a 560-person sales force in advance of its Monday launch of new attention deficit hyperactivity drug Vyvanse. Shire CEO Matthew Emmens said he is hopeful the drug will be able to ...

Shire has amassed a 560-person sales force to launch its new ADHD drug Vyvanse. The sales team began targeting specialist physicians treating ADHD including pediatricians, pediatric neurologists and ...

Treating attention deficit hyperactivity disorder (ADHD) with stimulant medication may reduce smoking risk, especially when medication is taken consistently, according to an analysis. ADHD is a common ...